<DOC>
	<DOCNO>NCT00967993</DOCNO>
	<brief_summary>The objective study see KRX-0502 ( ferric citrate ) safe effective dietary phosphate binder control manage serum phosphorus level patient end-stage renal disease ( ESRD ) .</brief_summary>
	<brief_title>Trial New Formulation KRX-0502 ( Ferric Citrate ) Patients With End-Stage Renal Disease</brief_title>
	<detailed_description>This multi-center , non-blinded , efficacy tolerability trial patient ESRD dialysis three time per week . Approximately 24 patient ( approximately twelve diabetic patient approximately twelve non-diabetic patient ) Israel initiate KRX-0502 ( ferric citrate ) . The study consist two-week washout period immediately follow six-week treatment period . Patients initiated study drug two three week .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>1 . Males nonpregnant , nonlactating female 2 . Age &gt; 18 year 3 . On thrice weekly hemodialysis least previous three month prior screen 4 . Serum phosphorus level â‰¥ 2.5 mg/dL &lt; 8.5 mg/dL Screening Visit ( Visit 0 ) 5 . Serum phosphorus level &gt; 5.5 mg/dL Study Drug Initiation Visit ( Visit 3 ) 6 . Taking 3 18 tablets/capsules/day calcium acetate calcium carbonate , lanthanum carbonate , sevelamer ( hydrochloride carbonate ) , combination agent report patient screen 7 . Serum ferritin &lt; 1000micrograms/L Transferrin Saturation ( TSAT ) &lt; 50 % 8 . Willing discontinue current phosphate binder ( ) initiate KRX0502 ( ferric citrate ) 9 . Willing able give inform consent 1 . Parathyroidectomy within six month prior Screening Visit ( Visit 0 ) 2 . Actively symptomatic gastrointestinal bleeding inflammatory bowel disease 3 . Serum phosphorus level &gt; 10.0 mg/dL document three monthly laboratory ( do routinely dialysis unit ) three month prior Screening Visit ( Visit 0 ) 4 . History multiple drug allergy 5 . History malignancy last five year ( treated cervical skin cancer may permit approve Keryx ) 6 . Previous intolerance oral ferric citrate 7 . Absolute requirement oral iron therapy 8 . Absolute requirement Vitamin C ( multivitamin [ Centrum , Nephrocaps , Renaphro , etc . ] allow ) 9 . Absolute requirement calcium , magnesium , aluminum contain drug meal 10 . Psychiatric disorder interfere patient 's ability comply study protocol 11 . Inability tolerate oral drug intake 12 . Planned surgery hospitalization study ( schedule outpatient access surgery allow ) 13 . Any medical condition render patient unable unlikely complete study would interfere optimal participation study produce significant risk patient 14 . Receipt investigational drug within 30 day randomization 15 . Inability cooperate study personnel history noncompliance 16 . Prior exposure ferric citrate 17 . Patients hemochromatosis Thalassemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>hyperphosphatemia</keyword>
	<keyword>end-stage renal disease</keyword>
	<keyword>ESRD</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>diabetes</keyword>
	<keyword>dialysis</keyword>
</DOC>